BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22204765)

  • 1. Molecular alterations underlying eosinophilic and mast cell malignancies.
    Sadrzadeh H; Abdel-Wahab O; Fathi AT
    Discov Med; 2011 Dec; 12(67):481-93. PubMed ID: 22204765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders.
    Valent P
    Blood Rev; 2009 Jul; 23(4):157-65. PubMed ID: 19246139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.
    Gotlib J; Akin C
    Semin Hematol; 2012 Apr; 49(2):128-37. PubMed ID: 22449623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mastocytosis: advances in diagnosis and treatment.
    Hungness SI; Akin C
    Curr Allergy Asthma Rep; 2007 Jul; 7(4):248-54. PubMed ID: 17547845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis, clinical features, and treatment advances in mastocytosis.
    Pardanani A; Akin C; Valent P
    Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
    Gotlib J
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):34-46. PubMed ID: 36485158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
    Gotlib J; Cross NC; Gilliland DG
    Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
    Savage N; George TI; Gotlib J
    Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
    Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
    Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.
    Valent P; Ghannadan M; Akin C; Krauth MT; Selzer E; Mayerhofer M; Sperr WR; Arock M; Samorapoompichit P; Horny HP; Metcalfe DD
    Eur J Clin Invest; 2004 Aug; 34 Suppl 2():41-52. PubMed ID: 15291805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mastocytosis.
    Metcalfe DD
    Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis, progression patterns and prognostication in mastocytosis.
    Sperr WR; Valent P
    Expert Rev Hematol; 2012 Jun; 5(3):261-74. PubMed ID: 22780207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.
    Gotlib J
    Curr Hematol Malig Rep; 2015 Dec; 10(4):351-61. PubMed ID: 26404639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clonal eosinophilia revealed by recurrent Staphylococcus aureus infection].
    Vandenbos F; Figueredo M; Dumon-Gubeno MC; Nicolle I; Tarhini A; Medioni LD; Naman H; Mouroux J
    Rev Pneumol Clin; 2011 Jun; 67(3):167-9. PubMed ID: 21665081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophilic myeloid disorders.
    Noel P
    Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors.
    Pittoni P; Piconese S; Tripodo C; Colombo MP
    Oncogene; 2011 Feb; 30(7):757-69. PubMed ID: 21057534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIT and mastocytosis.
    Lim KH; Pardanani A; Tefferi A
    Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mastocytosis - an update.
    Amon U; Hartmann K; Horny HP; Nowak A
    J Dtsch Dermatol Ges; 2010 Sep; 8(9):695-711; quiz 712. PubMed ID: 20678151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature.
    Kocabas CN; Yavuz AS; Lipsky PE; Metcalfe DD; Akin C
    J Allergy Clin Immunol; 2005 Jun; 115(6):1155-61. PubMed ID: 15940128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.